The Burzynski Research Institute (BRI) is using Syngene's Dyversity 2D image analyser and Dymension 2D analysis software to determine the molecular effects that compounds have on brain tumours.
Researchers at BRI, a US biopharmaceutical company, are using Dyversity and Dymension to analyse Coomassie blue stained 2D gels of proteins derived from glioblastoma cells.
Dyversity is also being utilised to image chemiluminescent Western blots of these proteins labelled with ECL.
The information generated is helping to determine what effects different compounds have on proteins associated with brainstem glioma, an aggressive type of brain tumour, and could lead to the introduction of treatments for this life-threatening disease.
Dr Sonali Patil, a scientist at BRI, said: 'In 2007, we decided to use a proteomics approach to see what affects the anti-cancer compounds we are developing have at the molecular level.
'We saw a Dyversity at another medical institute in Houston and were so impressed with all the features it had for the price that we knew we had to have one.
'Since then, we have used our own Dyversity in conjunction with the Dymension 2D analysis software to quantify spots on 2D gels because the two integrate well and the software layout makes this complicated analysis easy.
'We have even identified a couple of protein spots, which look promising,' added Patil.
